Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 87 points (0.5%) at 16,606 as of Thursday, May 8, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,938 issues advancing vs. 1,065 declining with 159 unchanged.

The Health Services industry currently sits up 0.3% versus the S&P 500, which is up 0.5%. Top gainers within the industry include Novadaq Technologies ( NVDQ), up 12.0%, CR Bard ( BCR), up 1.8%, Intuitive Surgical ( ISRG), up 1.7%, Becton Dickinson ( BDX), up 1.6% and Boston Scientific ( BSX), up 1.2%. On the negative front, top decliners within the industry include Humana ( HUM), down 1.7%, WellPoint ( WLP), down 0.6% and Fresenius Medical Care AG & Co. KGaA ( FMS), down 0.6%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. CareFusion ( CFN) is one of the companies pushing the Health Services industry higher today. As of noon trading, CareFusion is up $0.74 (1.9%) to $40.80 on average volume. Thus far, 611,390 shares of CareFusion exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $39.98-$40.82 after having opened the day at $39.98 as compared to the previous trading day's close of $40.06.

CareFusion Corporation, a medical technology company, provides various healthcare products and services. It offers product lines in the areas of medication management, infection prevention, operating room effectiveness, respiratory care, and surveillance and analytics. CareFusion has a market cap of $8.2 billion and is part of the health care sector. Shares are up 0.6% year-to-date as of the close of trading on Wednesday. Currently there are 5 analysts who rate CareFusion a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates CareFusion as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full CareFusion Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Quest Diagnostics ( DGX) is up $1.62 (2.9%) to $57.52 on heavy volume. Thus far, 2.6 million shares of Quest Diagnostics exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $56.34-$57.99 after having opened the day at $56.45 as compared to the previous trading day's close of $55.90.

Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company operates in two businesses, Diagnostic Information Services and Diagnostic Solutions. Quest Diagnostics has a market cap of $8.0 billion and is part of the health care sector. Shares are up 4.4% year-to-date as of the close of trading on Wednesday. Currently there are 2 analysts who rate Quest Diagnostics a buy, 4 analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Quest Diagnostics as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity, good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Quest Diagnostics Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Agilent Technologies ( A) is up $1.08 (2.0%) to $56.12 on light volume. Thus far, 788,835 shares of Agilent Technologies exchanged hands as compared to its average daily volume of 2.7 million shares. The stock has ranged in price between $54.69-$56.12 after having opened the day at $55.03 as compared to the previous trading day's close of $55.03.

Agilent Technologies, Inc. provides bio-analytical and electronic measurement solutions and services to the life sciences, chemical analysis, diagnostics and genomics, communications, and electronics industries worldwide. Agilent Technologies has a market cap of $18.3 billion and is part of the health care sector. Shares are down 3.8% year-to-date as of the close of trading on Wednesday. Currently there are 9 analysts who rate Agilent Technologies a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Agilent Technologies as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Agilent Technologies Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null